Table 1.

Reasons for patients receiving low-dose thrombolytic therapy

Age (year)	Gender	Reasons for using low-dose treatment	Weight of patients (kg)	Recommended dose based on patients’ weight (mg)	Difference of dose (mg)*
62	M	Received one dose LMWH at another hospital (we learned during the IV-tPA treatment and stopped)	60	54	4
53	M	Admission at near the treatment window limit and neurological deterioration during the IV-tPA treatment	74	66.6	16.6
87	F	Renal failure (regular hemodialysis)	80	72	22
66	F	Admission at near the treatment window limit and resistant HT requiring IV antihypertensive therapy	68	61.9	11.9
65	M	Allergic reaction	58	52.2	2.2
57	M	The reason was not stated in patients’ medical reports	86	77.4	27.4
62	M	•Renal failure (regular hemodialysis)	78	71.2	21.2
59	M	Received one dose LMWH at another hospital (we learned during the IV-tPA treatment and stopped)	78	71.2	21.2
69	F	Admission at near the treatment window limit and resistant HT requiring IV antihypertensive therapy	100	90	40
73	M	•Received one dose LMWH and presence of several risk factors for bleeding complication	72	64.8	14.8
91	F	•Advanced age and presence of several risk factors for bleeding complication	58	52.2	2.2
68	M	Treatment could not be completed because of delirium	80	72	22
53	M	The reason was not stated in patients’ medical reports	75	67.5	17.5
77	F	Resistant HT requiring IV antihypertensive therapy	80	72	22
75	M	Resistant HT requiring IV antihypertensive therapy	82	73.8	23.8
41	M	Admission at near the treatment window limit and resistant HT requiring IV antihypertensive therapy	62	55.8	5.8
74	F	Resistant HT requiring IV Antihypertensive therapy	70	63	13
76	F	Resistant HT requiring IV Antihypertensive therapy	74	66.6	15.6
81	F	•Renal failure	75	67.5	17.5

M: Male; F: Female; LMWH: Low molecular weighted heparin; HT: Hypertension; IV: Intravenous. All of the patients received IV rTPA at a total dose of 50 mg; *: Recommended treatment dose-received treatment dose; •: Patients initially scheduled for low-dose IV rTPA.